Condition (MeSH)
Retroperitoneal Fibrosis
ClinicalTrials.gov lists 16 trials for Retroperitoneal Fibrosis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
16 of the 16 trials are tagged with Retroperitoneal Fibrosis itself; the rest are tagged with a narrower condition beneath it.
When did Retroperitoneal Fibrosis trials start? (11)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 5 |
| 2018 | 1 |
| 2016 | 2 |
| 2013 | 1 |
| 2012 | 1 |
| 2010 | 1 |
| 2009 | 1 |
| 2007 | 1 |
Showing 10 of 11 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Retroperitoneal Fibrosis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 5 |
| Observational | 6 |
How many Retroperitoneal Fibrosis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 7 |
| Unknown status | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which drugs are being tested for Retroperitoneal Fibrosis? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Prednisone | 4 |
| RITUXIMAB | 2 |
| Corticosteroid | 1 |
| Sirolimus | 1 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Glucocorticoids | 2 |
| Tamoxifen Pill | 1 |
| Leflunomide Pill | 1 |
| Methotrexate+Prednisone | 1 |
| tocilizumab SC | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Retroperitoneal Fibrosis trials report? (6)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Amaurosis fugax | 1 | 1 |
| Klebsiella urinary tract infection | 1 | 1 |
| Legionella pneumophila pneumonia | 1 | 1 |
| Surgery for pseudotumor | 1 | 1 |
| cold agglutininmediated | 1 | 1 |
Showing 5 of 6 adverse events.
Which publications cover Retroperitoneal Fibrosis? (28)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. | Journal of autoimmunity | 2025 | Yes |
| Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. | Annals of the rheumatic diseases | 2019 | Yes |
| [<sup>18</sup>F]-Fluorodeoxyglucose Positron Emission Tomography in the Diagnosis, Treatment Stratification, and Monitoring of Patients with Retroperitoneal Fibrosis: A Prospective Clinical Study. | European urology | 2017 | Yes |
| Small-bowel neuroendocrine tumor and retroperitoneal fibrosis: efficacy of octreotide and tamoxifen. | Tumori | 2015 | Yes |
| Immunology of IgG4-related disease. | Clinical and experimental immunology | 2015 | Yes |
Showing 5 of 28 publications.
Prevalence (9)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| IgG4-related retroperitoneal fibrosis | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| IgG4-related retroperitoneal fibrosis | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
| IgG4-related retroperitoneal fibrosis | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| IgG4-related retroperitoneal fibrosis | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| IgG4-related retroperitoneal fibrosis | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 9 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| IgG4-related retroperitoneal fibrosis | 49041 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| IgG4-related retroperitoneal fibrosis | 49041 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors and sub-conditions in mesh.